scispace - formally typeset
P

Pietro Fratta

Researcher at UCL Institute of Neurology

Publications -  128
Citations -  7878

Pietro Fratta is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Frontotemporal dementia. The author has an hindex of 37, co-authored 111 publications receiving 5728 citations. Previous affiliations of Pietro Fratta include The Catholic University of America & Vita-Salute San Raffaele University.

Papers
More filters
Journal ArticleDOI

C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.

TL;DR: In vitro and in vivo models to dissect repeat RNA and dipeptide repeat protein toxicity are developed, consistent with a dual toxicity mechanism, whereby both arginine-rich proteins and repeat RNA contribute to C9orf72-mediated neurodegeneration.
Journal ArticleDOI

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

Wouter van Rheenen, +187 more
- 01 Sep 2016 - 
TL;DR: Evidence of ALS being a complex genetic trait with a polygenic architecture is established and the SNP-based heritability is estimated at 8.5%, with a distinct and important role for low-frequency variants (frequency 1–10%).
Journal ArticleDOI

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Aude Nicolas, +435 more
- 21 Mar 2018 - 
TL;DR: Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia and Charcot-Marie-Tooth type 2.
Journal ArticleDOI

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis

TL;DR: Exome sequencing data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration in ALS kindreds and observed MATR3 pathology in ALS-affected spinal cords with and withoutMATR3 mutations.
Journal ArticleDOI

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.

TL;DR: This report provides Class III evidence that the NfL electrochemiluminescence immunoassay accurately distinguishes patients with sporadic ALS from healthy controls and offers potential for N fL as a pharmacodynamic biomarker in future therapeutic trials.